MAESTROVE (2021-2025)
Une thérapie matricielle pour optimiser la thérapie basée sur les vésicules extracellulaires dérivées de MSC pour protéger et réparer le cerveau ischémié
https://anr.fr/Project-ANR-21-CE18-0029/
Regenerative therapy based on the use of mesenchymal stem cells (MSCs) is a promising approach for the treatment of stroke. The beneficial effects of MSC seem to be mainly related to the secretion of cellular factors and/or extracellular vesicles (EV). The heparan sulphates present on the surface of producer and recipient cells as well as on the EV themselves, could play a critical role in the communication relayed by these EV. The MAESTROVE project aims to determine whether the combination of EV from human MSC with a heparan sulfate mimetic agent optimizes the effects of EV on tissue regeneration and functional recovery after stroke treatment, thus opening a new and rapid perspective for a more easily industrializable development of a stroke treatment, through innovative approaches and models developed by 4 partners.
Partners : ISTCT (Caen, FR), Gly-CRRET, (Créteil, FR) MSC (Paris, FR), OTR3 S.A.S (Paris, FR)
Français (France) 
English (United Kingdom) 
